KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting

KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting

FRAMINGHAM, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”), a company of the Chiesi Group, today announced the presentation of new clinical and real-world research evaluating sebetralstat at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix (November 12-16). The five presentations highlight patient-reported satisfaction with sebetralstat, reasons for treatment switching, l…